Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -49.12% is 58% above its 5-year average of -117.36%, near the high end of its 5-year range (-362.89%–-18.34%).
64.83% below its 12-month average of -29.80%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -13.33%.
RETURN ON ASSETS (ROA)
-49.12%
RETURN ON ASSETS (ROA) AVG TTM
-29.80%
RETURN ON ASSETS (ROA) AVG 3Y
-67.98%
RETURN ON ASSETS (ROA) AVG 5Y
-117.36%
RETURN ON ASSETS (ROA) AVG 10Y
-122.29%
RETURN ON ASSETS (ROA) AVG 15Y
-108.54%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-64.83%
CURRENT VS 3Y AVG
+27.75%
CURRENT VS 5Y AVG
+58.15%
CURRENT VS 10Y AVG
+59.83%
CURRENT VS 15Y AVG
+54.74%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.07%
median of 664 covered companies
CURRENT VS SECTOR MEDIAN
-63.35%
vs the sector median at left
Dare Bioscience, Inc.
Market Cap
$12.57M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$12.63M
Return on Assets (ROA)
-216.84%
TTM Avg
-118.20%
3Y Avg
-6127.40%
5Y Avg
-4092.56%
Market Cap
$12.12M
Return on Assets (ROA)
-13.01%
TTM Avg
-15.22%
3Y Avg
-24.53%
5Y Avg
-20.43%
Market Cap
$12.94M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$12.73M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$12.95M
Return on Assets (ROA)
-27.12%
TTM Avg
-32.94%
3Y Avg
-35.27%
5Y Avg
-29.16%
Market Cap
$11.73M
Return on Assets (ROA)
-90.19%
TTM Avg
-82.55%
3Y Avg
-92.57%
5Y Avg
-79.83%
Market Cap
$11.94M
Return on Assets (ROA)
-77.94%
TTM Avg
-178.68%
3Y Avg
-1009.31%
5Y Avg
-2782.57%
Market Cap
$13.71M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dare Bioscience, Inc. (DARE) | $12.57M | -49.12% | -29.80% | -67.98% | -117.36% |
| Lantern Pharma Inc. (LTRN)vs › | $12.63M | -216.84% | -118.20% | -6127.40% | -4092.56% |
| IRIDEX Corporation (IRIX)vs › | $12.12M | -13.01% | -15.22% | -24.53% | -20.43% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.94M | -60.93% | -160.25% | -205.49% | -152.09% |
| Cytosorbents Corporation (CTSO)vs › | $12.73M | -47.98% | -31.15% | -42.27% | -34.21% |
| Optimi Health Corp. (OPTH)vs › | $12.95M | -27.12% | -32.94% | -35.27% | -29.16% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.73M | -90.19% | -82.55% | -92.57% | -79.83% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.94M | -77.94% | -178.68% | -1009.31% | -2782.57% |
| IN8bio, Inc. (INAB)vs › | $13.71M | -85.85% | -102.78% | -95.22% | -76.09% |
| Vyome Holdings, Inc. (HIND)vs › | $13.34M | -123.23% | -153.35% | -205.77% | -166.29% |
ROA
-49.1%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -41.26% |
| 2024-12-31 | -18.34% |
| 2023-12-31 | -141.72% |
| 2022-12-31 | -70.61% |
| 2021-12-31 | -69.34% |
| 2020-12-31 | -362.89% |
| 2019-12-31 | -191.65% |
| 2018-12-31 | -213.85% |
| 2017-12-31 | -80.67% |
| 2016-12-31 | -104.29% |
| 2015-12-31 | -50.62% |
| 2014-12-31 | -43.72% |
| 2013-12-31 | -251.11% |
| 2012-12-31 | -125.14% |
| 2011-12-31 | -117.21% |
